Cooley is a full service global law firm, having more than 900 lawyers across 13 offices in China, Europe and the United States. For over 40 years, Cooley has played an instrumental role in the growth of many of the most sophisticated companies in the life sciences industry, focusing on corporate partnering, licensing, complex mergers, acquisitions and disposition transactions, local and cross-border intellectual property issues, regulatory counselling, capital markets, supply and distribution arrangements and other commercial transactions. Our experience representing life sciences companies and investors also gives us insight into financings of companies at all stages of development.
We have been advising on Greater China-related matters over three decades and recently expanded our Asia-Pacific presence by launching the Beijing office. It is Cooley’s 13th office worldwide and its second in China, having opened in Shanghai in 2011.
Genor Biopharma Co. Ltd. was founded in December 2007. It is an innovation-driven international biopharmaceutical company, focusing on development and commercialization of therapeutic monoclonal antibodies (mAbs), Fc-fusion proteins and recombinant therapeutic proteins. Currently Genor has 10 products in pipeline, and got 11 INDs,several of which have entered clinical stage. In December 2013, Genor was acquired by Walvax Biotechnology Co., Ltd (Walvax: 300142), a public listed biopharma in China.
Currently, Genor has more than 250 employees, most of which is R&D people. Genor have built a fully integrated R&D team led by a highly experienced Core Management Team. Each of the Core Management Team member has more than 15~20 years of industry experiences, and many of them came back from major western biopharmaceutical giants such as Amgen.
Genor has built end-to-end capabilities in research, development, production of therapeutic mAbs with mature technology platforms. Genor now has more than 6000 square meters of facility space, including R&D Labs, Process Development Labs, Analytical & Quality Center, and a cGMP Clinical Production Facility. A commercial scale cGMP production facility in Yuxi has been put into operation.
Hangzhou Economic and Technological Development Area (HEDA) is a comprehensive development area combining advanced manufacturing park, university town and comprehensive bonded zone. It also serves as one of the sub-centers of Hangzhou. HEDA has been dubbed as the national innovation and entrepreneurship demonstration base, the national demonstration area for quality and safety of imported and exported bio-medicines (biological products), provincial level featured town of Zhejiang, the innovation base for invigorating trade with bio-medical science and technology of Zhejiang Province and the essential area of “New Medicine Port” of Hangzhou. As one of the leading feature industries of HEDA, its biopharm industry production value reached 30 billion Yuan. The growth rate has stayed above 15%. HEDA takes nearly 40% of the biopharm industry gross value of Hangzhou.
Established in 1989, OrbiMed is the world’s largest healthcare and life sciences-dedicated investment firm. OrbiMed manages over USD$11 billion assets, including several PE/VC funds, hedge funds and mutual funds. Since the inception of its private equity investment activities in 1993, OrbiMed has successfully invested in over 170 private companies across a wide range of therapeutic categories and stages of development, over 90 of which have been either listed or acquired. OrbiMed has continued strong performance in public equity as well, with ~27×cumulative return in the past 20 years. OrbiMed’s investment team includes over 80 experienced professionals with backgrounds in science, medicine, industry, finance and law. OrbiMed Asia, with offices in Shanghai and Mumbai, manages OrbiMed Asia Partners (OAP), the first pan-Asia healthcare and life sciences-dedicated private equity fund, with approximately USD$200 million under management. OAP has made investments in 20 companies.
Asymchem is a global advanced CDMO company, focusing on provide biopharmaceutical companies from preclinical to commercialization manufacturing solution.
BioTrack capital is a healthcare fund focusing on early stage innovative technology, product and business model and middle/late stage M&A fund collaborating with listed companies. BioTrack is mainly invest in biotech, medical device/diagnostics , medical service and medical IT.